Related Experiment Videos
Radioimmunoimaging in malignant melanoma with monoclonal antibodies
L Repetto1, G Scopinaro, A Michelotti
1Divisione Oncologica Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italia.
Abstract:
Twenty-five patients with cutaneous melanoma were imaged with F(ab')2 fragments of antimelanoma monoclonal antibody (MoAb) 225.28S labeled with 99mTc and 131I or 111In. Out of 16 patients without evidence of metastatic lesions, 6 false-positive cases were observed. Only 4 out of 9 patients with known lesions showed positive findings (globally 8 of 19 metastatic sites). In conclusion, antimelanoma MoAb was of little help in radioimaging and stating this disease.
Insights
Antimelanoma monoclonal antibody (MoAb) radioimaging showed limited utility for detecting metastatic cutaneous melanoma. The technique yielded several false positives and missed many known metastatic sites, hindering accurate disease staging.
Area of Science:
- Oncology
- Immunology
- Nuclear Medicine
Background:
- Cutaneous melanoma diagnosis and staging are critical for treatment planning.
- Monoclonal antibodies (MoAb) offer targeted approaches for cancer detection.
- Radioimaging with labeled MoAb fragments is explored for improved diagnostic accuracy.
Purpose of the Study:
- To evaluate the diagnostic performance of F(ab')2 fragments of antimelanoma MoAb 225.28S in radioimaging melanoma patients.
- To assess the effectiveness of this MoAb in detecting metastatic lesions.
- To determine the clinical utility of antimelanoma MoAb for staging cutaneous melanoma.
Main Methods:
- Twenty-five patients with cutaneous melanoma underwent radioimaging.
- F(ab')2 fragments of antimelanoma MoAb 225.28S were labeled with radioisotopes (99mTc, 131I, or 111In).
- Imaging results were compared against clinical and pathological staging.
Main Results:
- Out of 16 patients without initially detected metastatic lesions, 6 false-positive results were recorded.
- Only 4 of 9 patients with known metastatic sites showed positive findings on imaging.
- A total of 8 out of 19 known metastatic sites were identified, indicating low sensitivity.
Conclusions:
- Antimelanoma MoAb radioimaging demonstrated limited value in detecting and staging cutaneous melanoma.
- The observed false-positive rates and missed metastatic sites reduce its clinical applicability.
- Further research is needed to improve the efficacy of immunoscintigraphy for melanoma staging.